Protein Screening for Targeted Biomarker Discovery
BioXpedia provide protein biomarker screening using Olink Proteomics. Biomarkers for early diagnosis, prognosis, patient stratification or monitoring treatment response is increasing in demand with the focus on personalised medical treatment.
Protein biomarkers offer a significantly higher degree of differentiated information compared to genomic biomarkers. In addition, proteins represent the direct functionality which makes them essential in understanding disease pathology and associated biological processes.
Targeted protein screening by Olink offers a unique way of investigating a selected part of the proteome in the search for disease specific biomarkers, within multiple areas such as immunology, cardiovascular disease, neurology and oncology.
Immunoassay Detection Quantified by qPCR Amplification
Olink Proteomics has developed a series of protein biomarker panels, which use a unique technology (Proximity Extension Assay) enabling high-throughput, multiplex immunoassay-qPCR that measures 92 proteins across 96 samples simultaneously.
The main steps involved in the protein quantification analysis are outlined in the figure. Each immunoassay targeting a specific protein in a panel consists of two antibodies. The antibodies are labelled with one oligo each, which have a region of complementarity to each other.
When the two antibodies bind simultaneously to the protein, the oligos will be in such proximity that they will hybridize, and the sequences are extended to form a PCR target sequence. The resulting sequence is subsequently amplified and quantified by fluorescence intensity using the Fluidigm PCR system.
The innovative dual recognition, DNA-coupled methodology provides exceptional readout specificity, enabling high multiplex, rapid throughput protein biomarker analysis without compromising on data quality and assay robustness.
Quantify 92 Proteins Simultaneously
The immunoassays are developed to be multiplexed in defined panels targeting 92 proteins, and has been validated primarily on plasma and serum, of which only 1 µl is required, however the assay is compatible with almost all sample types, as visualised in the figure.
Currently, 14 human panels exist, which are either disease focused or related to specific processes in the body. Additionally, for translational mouse model studies, an exploratory mouse panel has also been developed allowing protein screening in mouse plasma.
The content of each panel can be found by clicking on the panels below, including information about the number of proteins relevant to specific disease areas and biological processes:
Sample types suitable for biomarker discovery
Olink Proteomics for large-scale biomarker screeningand proteins.